Branded Legacy Inc - BLEG STOCK NEWS

Branded Legacy, Inc. (OTC.PK: BLEG) has secured a significant client, Monster Group, Inc., with $70,000,000 in annual revenue. This partnership is expected to boost Branded Legacy's revenue to over $10,000,000 annually by 2025. The company's subsidiary, Sycamore BioPharma, will provide high-quality mitragynine salt for the client's product lines sold across the Middle East, Europe, and North America.

The current supply line is generating approximately $60,000 weekly for Branded Legacy, with a 500% growth target set for the next six months. The company plans to take over lab operations for this client within 6 to 10 months. Additionally, Branded Legacy's subsidiary Royal Biotek is in negotiations with a large distributor for Delta 8 and Delta 9 distillate, potentially leading to similar revenue figures.

CEO Dave Oswald stated that this development positions Branded Legacy to be self-funded moving forward, reducing the need for additional funding. The company is also in talks with several potential acquisition candidates to complement its existing operations and strategic growth plans.

Fifty 1 Labs and All-In-Extracts have entered a joint venture to develop a new testosterone-boosting supplement. Combining Fifty 1 Labs' supplement expertise and All-In-Extracts' advanced botanical extraction methods, they aim to create a product that supports natural testosterone production and overall well-being.

Clinical trials will begin promptly to ensure safety, efficacy, and quality, with the product expected to launch in Q4 2024 initially in the U.S., followed by international expansion. The supplement targets common issues such as low energy and reduced muscle mass and is intended for both men and women.

Both companies emphasize transparency, safety, and quality, with plans for an extensive marketing campaign to educate consumers.

Branded Legacy (OTC.PK: BLEG) has announced an exclusive extraction agreement with Botany Evolution, a leading kava distributor. This partnership is expected to generate over $1.25 million in annual profits. Royal Biotek will produce kava extracts, including a 30% kava extract and a 70% kavalactone paste. Botany Evolution will provide all necessary kava inputs. This agreement aims to meet the growing demand for kava in wellness and recreational markets. The companies plan to explore further projects, including white-label gummies and beverages.

Branded Legacy (OTCPK: BLEG), a leading wellness and skincare provider, has announced a collaboration with renowned celebrity tattoo artist Kat Tat. This partnership has resulted in the creation of Enigma by Kat Tat, a premium shea butter-based tattoo aftercare product aimed at enhancing and preserving the beauty of fresh tattoos. Kat Tat, known for her appearances on VH1's 'Black Ink Crew: Chicago,' brings her extensive industry experience to the formulation of the product. Enigma by Kat Tat is expected to boost Branded Legacy's product portfolio and brand visibility, leveraging Kat Tat's celebrity status to increase consumer interest and shareholder value. The product will soon be available for purchase online and at select retailers nationwide.

Branded Legacy (OTCQB: BLEG), a leading wellness product provider, invites shareholders to an exclusive open house on June 14th to celebrate the new extraction and manufacturing equipment. The company announced a share buyback initiative and pledged to maintain the current authorized share count, avoiding reverse splits unless necessary for uplisting. Additionally, Branded Legacy introduced the Royal Biotek Kava Vape, receiving strong distributor feedback and pre-sales. The company reported a net income of $3.8M for 2023, boosted by the retirement of over 2.4 billion shares, and has signed multiple white label contracts for 2024.

Branded Legacy, Inc. reports a significant net income of over $3.8 million for the fiscal year 2023, driven by strategic retirements of shares. The company's assets have surpassed $3.7 million in 2024, with expansions and acquisitions boosting capabilities and revenue. Dr. Mark T. Hamann joins for clinical trials, following the acquisition of Sycamore BioPharma, Inc. Strategic acquisitions of companies like MariJ Pharmaceuticals, Inc. and All In Extracts further enhance Branded Legacy's market position and product offerings.

Royal Biotek, a subsidiary of Branded Legacy, Inc. (Symbol: $BLEG), announces the expansion of its Everglade line, a collection of cannabis products for Surge Distribution Co. This move showcases Royal Biotek's dedication to customized cannabis solutions. CEO David Oswald is optimistic about the growth.

Branded Legacy, Inc. strengthens its market position through a white label deal with Kava & Hobbs, for Kava Vape formulation, boosting quarter 1 revenue. The company also expands its portfolio with the acquisition of Sycamore BioPharma, Inc., securing assets and key personnel for clinical trials and FDA approval processes.

Branded Legacy (BLEG) announces the acquisition of Sycamore BioPharma, a developer of plant-based pharmaceuticals, strengthening its position in the biotech sector. The acquisition brings assets exceeding $2 million, including $500,000 in inventory, and key personnel for advancing clinical trials. Sycamore BioPharma is known for its wellness solutions, aligning with Branded Legacy's focus on quality and natural ingredients.